Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
CAS RN: 1225451-84-2 | Product Number: K0060
SKLB1002
×
![]()
×
Purity: >98.0%(HPLC)
Synonyms:
- 6,7-Dimethoxy-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]quinazoline
- 2-[(6,7-Dimethoxyquinazolin-4-yl)thio]-5-methyl-1,3,4-thiadiazole
Product Documents:
| Size | Unit Price | Belgium | Japan* | Quantity |
|---|---|---|---|---|
| 25MG |
141,00 €
|
1 | ≥40 |
|
| 100MG |
466,00 €
|
1 | 27 |
|
*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).
| Product Number | K0060 |
| Purity / Analysis Method | >98.0%(HPLC) |
| Molecular Formula / Molecular Weight | C__1__3H__1__2N__4O__2S__2 = 320.39 |
| Physical State (20 deg.C) | Solid |
| Storage Temperature | Frozen (<0°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 1225451-84-2 |
| Reaxys Registry Number | 24520489 |
| PubChem Substance ID | 354335818 |
| MDL Number | MFCD27938707 |
Specifications
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 191.0 to 195.0 °C |
| NMR | confirm to structure |
Properties (reference)
| Melting Point | 193 °C |
GHS
| Pictogram |
|
| Signal Word | Danger |
| Hazard Statements | H301 : Toxic if swallowed. |
| Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
Related Laws:
Transport Information:
| UN Number | UN2811 |
| Class | 6.1 |
| Packing Group | III |
| HS Number | 2934999090 |
Application
SKLB1002: A Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitor
SKLB1002 has been reported as a vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor, as an efficient anti-angiogenesis agent. Experimental evidence demonstrated VEGFR has been associated with tumor angiogenesis, thus making it a valuable and attractive target for drug design for therapeutic applications.
References
- SKLB1002, a Novel Potent Inhibitor of VEGF Receptor 2 Signaling, Inhibits Angiogenesis and Tumor Growth In Vivo
- SKLB1002, a novel inhibitor of VEGF receptor 2 signaling, induces vascular normalization to improve systemically administered chemotherapy efficacy
- Synergic antitumor effect of SKLB1002 and local hyperthermia in 4T1 and CT26
PubMed Literature
Articles/Brochures
TCIMAIL
Product Documents (Note: Some products will not have analytical charts available.)
Safety Data Sheet (SDS)
Please select Language.
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
Sample C of A
This is a sample C of A and may not represent a recently manufactured lot of the product.
A sample C of A for this product is not available at this time.
Analytical Charts
Please enter Lot Number
Incorrect Lot Number. Please input only the 4-5 alphanumeric characters before the hyphen.
The requested analytical chart is not available. Sorry for the inconvenience.